• 1
    Wallis RS, Johnson JL. Adult tuberculosis in the 21st century: pathogenesis, clinical features, and management. Curr Opin Pulm Med 2001; 7: 12432.
  • 2
    Jaramillo E. DOTS-Plus and the Green Light Committee. Presented at “Meet the Expert” session of the 33rd IUATLD World Conference on Lung Health; Montreal, Quebec, Canada; 2002.
  • 3
    Targeted tuberculin testing and treatment of latent tuberculosis infection: joint statement of the American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med 2000; 161: S22147.
  • 4
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098104.
  • 5
    Carmona L, Hernandez-Garcia C, Vadillo C, Pato E, Balsa A, Gonzalez-Alvaro I, et al, and the EMECAR Study Group. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 14369.
  • 6
    Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 21227.
  • 7
    Schatz M, Patterson R, Kloner R, Falk J. The prevalence of tuberculosis and positive tuberculin skin tests in a steroid-treated asthmatic population. Ann Intern Med 1976; 84: 2615.
  • 8
    Bovornkitti S, Kangsadal P, Sathirapat P, Oonsombatti P. Reversion and reconversion rate of tuberculin skin reactions in correction with the use of prednisone. Dis Chest 1960; 38: 515.
  • 9
    Kim HA, Yoo CD, Baek HJ, Lee EB, Ahn C, Han JS, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998; 16: 913.
  • 10
    Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 6869.
  • 11
    Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 7668.
  • 12
    Bradford Hill A. The environment and disease: association of causation. Proc Royal Soc Med 1965; 58: 295300.
  • 13
    Rose AM, Watson JM, Graham C, Nunn AJ, Drobniewski F, Ormerod LP, et al. Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax 2001; 56: 1739.
  • 14
    Centers for Disease Control and Prevention. URL:
  • 15
    Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 3729.
  • 16
    Orme IM, Andersen P, Boom WH. T cell response to Mycobacterium tuberculosis. J Infect Dis 1993; 167: 148197.
  • 17
    Balow JE, Rosenthal AS. Glucocorticoid suppression of macrophage migration inhibitory factor. J Exp Med 1973; 137: 103141.
  • 18
    Rinehart JJ, Sagone AL, Balcerzak SP, Ackerman GA, LoBuglio AF. Effects of corticosteroid therapy on human monocyte function. N Engl J Med 1975; 292: 23641.
  • 19
    Segal BH, Sneller MC. Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am 1997; 23: 21937.
  • 20
    Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976; 84: 30415.
  • 21
    Palmer CE, Jablon S, Edwards PQ. Tuberculosis morbidity of young men in relation to tuberculin sensitivity and body build. Am Rev Tuberc 1957; 76: 51739.
  • 22
    Gajalakshmi V, Peto R, Kanaka TS, Jha P. Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls. Lancet 2003; 362: 50715.
  • 23
    Boelaert JR, Gomes MS, Gordeuk VR. Smoking, iron, and tuberculosis. Lancet 2003; 362: 12434.